CN106414472A - 用于靶向癌症和产生抗体的抗神经节苷脂化合物 - Google Patents

用于靶向癌症和产生抗体的抗神经节苷脂化合物 Download PDF

Info

Publication number
CN106414472A
CN106414472A CN201480073838.1A CN201480073838A CN106414472A CN 106414472 A CN106414472 A CN 106414472A CN 201480073838 A CN201480073838 A CN 201480073838A CN 106414472 A CN106414472 A CN 106414472A
Authority
CN
China
Prior art keywords
ganglioside
carbohydrate
cancer
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480073838.1A
Other languages
English (en)
Chinese (zh)
Inventor
H·尤里·萨拉戈维
佟文勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reality Pharmaceuticals Ltd
Original Assignee
Reality Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reality Pharmaceuticals Ltd filed Critical Reality Pharmaceuticals Ltd
Publication of CN106414472A publication Critical patent/CN106414472A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480073838.1A 2013-12-06 2014-12-04 用于靶向癌症和产生抗体的抗神经节苷脂化合物 Pending CN106414472A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912684P 2013-12-06 2013-12-06
US61/912,684 2013-12-06
PCT/CA2014/051165 WO2015081438A1 (en) 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies

Publications (1)

Publication Number Publication Date
CN106414472A true CN106414472A (zh) 2017-02-15

Family

ID=53272688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480073838.1A Pending CN106414472A (zh) 2013-12-06 2014-12-04 用于靶向癌症和产生抗体的抗神经节苷脂化合物

Country Status (7)

Country Link
US (1) US10363305B2 (enExample)
EP (2) EP3957327A1 (enExample)
JP (1) JP2016539172A (enExample)
CN (1) CN106414472A (enExample)
CA (1) CA2968995A1 (enExample)
ES (1) ES2904533T3 (enExample)
WO (1) WO2015081438A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786586B2 (en) 2016-12-23 2023-10-17 Aoa Dx Carbohydrate structures and uses thereof
US20250277793A1 (en) * 2020-10-05 2025-09-04 Aoa Dx Compositions and methods for cancer diagnosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (en) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU685776B2 (en) * 1993-01-22 1998-01-29 Sloan-Kettering Institute For Cancer Research Ganglioside-KLH conjugate vaccines with QS-21
WO2002062810A2 (en) 2000-11-29 2002-08-15 Bracco International B.V. Linkable sialyl lewis x analogs
JP2003073397A (ja) * 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
JP4742339B2 (ja) * 2005-06-14 2011-08-10 独立行政法人産業技術総合研究所 シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
US20090181362A1 (en) * 2005-09-02 2009-07-16 Yasuo Suzuki Method for determination of recognition specificity of virus for receptor sugar chain
JP2008031156A (ja) * 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (en) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HELEN ZHANG,ET AL.,: "Antibodies against GD2 Ganglioside Can Eradicate Syngeneic Cancer Micrometastases1", 《CANCER RESEARCH》 *
JEFFREY P. THOMPSON,ET AL.,: "Oligosaccharide-derivatized dendrimers: defined multivalent inhibitors of the adherence of the cholera toxin B subunit and the heat labile enterotoxin of E. coli to GM1", 《GLYCOCONJUGATE JOURNAL》 *
LEI QIU,ET AL.,: "Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy", 《CANCER IMMUNOL IMMUNOTHER》 *
RENA D. ASTRONOMO,ET AL.,: "Carbohydrate vaccines: developing sweet solutions to sticky situations?", 《NATURE REVIEWS DRUG DISCOVERY 》 *
YOSHIMI MUROZUKA,ET AL.,: "Lyso-GM3, its dimer, and multimer: their synthesis, and their effect on epidermal growth factor-induced receptor tyrosine kinase", 《GLYCOCONJ J》 *

Also Published As

Publication number Publication date
EP3077405A1 (en) 2016-10-12
EP3957327A1 (en) 2022-02-23
US10363305B2 (en) 2019-07-30
EP3077405B1 (en) 2021-11-03
US20160303227A1 (en) 2016-10-20
CA2968995A1 (en) 2015-06-11
JP2016539172A (ja) 2016-12-15
EP3077405A4 (en) 2017-08-09
WO2015081438A1 (en) 2015-06-11
ES2904533T3 (es) 2022-04-05

Similar Documents

Publication Publication Date Title
CA2959030C (en) Novel glycan conjugates and use thereof
JP6050227B2 (ja) 多価糖ペプチド構築物およびその使用
Yin et al. Significant impact of immunogen design on the diversity of antibodies generated by carbohydrate-based anticancer vaccine
CN109890417A (zh) 癌的治疗和/或预防用药物组合物
JP2009528267A (ja) 治療を増強するグルカン
US20030170249A1 (en) Vaccines directed to cancer-associated carbohydrate antigens
CN110475566A (zh) 工程细胞和使用方法
US20210137987A1 (en) Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies
JP4713638B2 (ja) ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン
KR102167438B1 (ko) 변형된 당지질들 및 이들을 제조하고 사용하는 방법들
Mat Rani et al. Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers
US20240042000A1 (en) Carbohydrate structures and uses thereof
RU2627175C2 (ru) Новый пептид, имеющий 5 соединенных эпитопов ctl
Marqvorsen et al. Going native: synthesis of glycoproteins and glycopeptides via native linkages to study glycan-specific roles in the immune system
CN106414472A (zh) 用于靶向癌症和产生抗体的抗神经节苷脂化合物
Hung et al. GD2-Targeted immunotherapy of neuroblastoma
KR20090047290A (ko) 엑소좀 및 이를 함유한 암 백신 조성물
Ma et al. Enhanced Antitumor Immunity of a Globo H‐Based Vaccine Enabled by the Combination Adjuvants of 3D‐MPL and QS‐21
Du et al. Diphtheria toxoid-derived T-helper epitope and α-galactosylceramide synergistically enhance the immunogenicity of glycopeptide antigen
HK40064500A (en) Anti-ganglioside compound for targeting cancer and generating antibodies
US20050169929A1 (en) Use of a vaccine for active immunization against cancer
Rashidijahanabad Development of Carbohydrate Based Conjugate Vaccines Using Qβ Virus Like Particles with Anti-bacterial or Anti-cancer Properties
Tong et al. A synthetic GD2 carbohydrate tetramer vaccine elicits tumor-killing antibodies and is therapeutic against GD2+ tumors
Apostolopoulos et al. Carbohydrate-Based Targets and Vehicles for Cancer and Infectious Diseases Vaccines
Apostolopoulos Carbohydrate-Based Targets and Vehicles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170215